Trial *
Publication Maldonado V, INT IMMUNOPHARMACOL (2020) (published paper)
Dates: 2020-07-01 to 2020-08-31
Funding: No specific funding (None)
Conflict of interest: No

Methods
RCT
Location : Single center / Mexico
Follow-up duration (days): *
Inclusion criteria
  • Pneumonia suspected of being caused by SARS-COV2 with clinical symptoms and signs such as fever, fatigue, dry cough, anorexia, myalgia, dyspnea, sputum production, dysgeusia, and anosmia
  • infiltrates in chest imaging studies (plain radiography or tomography)
  • confirmation of SARS-CoV-2 infection by viral PCR
  • signed informed consent for receiving their primary treatment and pentoxifylline if selected to be included in the pentoxifylline group
Exclusion criteria
  • Pregnant or lactating patients
  • those who did not wish to participate in the study or had an allergy, intolerance, or contraindication for pentoxifylline.
Interventions
Treatment
Pentoxifylline
400 mg orally 3 times a day until discharge
Control
Standard care

Participants
Randomized
participants :
Pentoxifylline =36
Standard care=18
Characteristics of participants
N= 54
Mean age : NR
21 males
Severity : Mild: n=0 / Moderate: n=* / Severe: n=* Critical: n=*
Number of vaccinated participants: NR
Primary outcome
In the register
NR
In the report
NR
Documents
available

Protocol

NR

Statistical plan

NR

Data-sharing willing stated in the publication:

Not reported
Risk of bias
Overall
The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review
*
General comment The overall follow-up time period for this study, as well as the appropriate timepoints for outcomes, could not be determined at the time of extraction. This study is pending contact with authors.
Only the available version of the pre-print article was used for in data extraction and risk of bias assessment. Neither the trial protocol not the registry were available at the time of data extraction. No target sample was prespecified. 1 patient withdrew because of adverse event (abdominal pain), 15 additional patients had incomplete data.